CLINICAL TRIALS PROFILE FOR SORIVUDINE

Clinical Trials for Sorivudine

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000953 ↗	Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients	Completed	Bristol-Myers Squibb	Phase 2	To compare the efficacy of oral sorivudine (brovavir) and oral acyclovir for the treatment of localized herpes zoster in HIV-infected patients. HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used to treat VZV infections in the HIV population. Since no data from controlled studies are available to define the role of antiviral therapy for VZV infections in HIV-infected patients, a study is needed to test the relative efficacy of brovavir, an experimental antiviral drug, versus that of acyclovir.
NCT00000953 ↗	Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients	Completed	Glaxo Wellcome	Phase 2	To compare the efficacy of oral sorivudine (brovavir) and oral acyclovir for the treatment of localized herpes zoster in HIV-infected patients. HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used to treat VZV infections in the HIV population. Since no data from controlled studies are available to define the role of antiviral therapy for VZV infections in HIV-infected patients, a study is needed to test the relative efficacy of brovavir, an experimental antiviral drug, versus that of acyclovir.
NCT00000953 ↗	Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	To compare the efficacy of oral sorivudine (brovavir) and oral acyclovir for the treatment of localized herpes zoster in HIV-infected patients. HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used to treat VZV infections in the HIV population. Since no data from controlled studies are available to define the role of antiviral therapy for VZV infections in HIV-infected patients, a study is needed to test the relative efficacy of brovavir, an experimental antiviral drug, versus that of acyclovir.
NCT00002358 ↗	A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV	Completed	Bristol-Myers Squibb	Phase 3	To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.

Clinical Trial Conditions for Sorivudine

Condition Name

Condition Name
Intervention	Trials
Chickenpox	2
HIV Infections	2
Rectal Cancer	2
Colorectal Cancer	1

Condition MeSH

Condition MeSH
Intervention	Trials
Herpes Zoster	2
Chickenpox	2
Rectal Neoplasms	2
HIV Infections	2

Clinical Trial Locations for Sorivudine

Trials by Country

Trials by Country
Location	Trials
United States	27

Trials by US State

Trials by US State
Location	Trials
Texas	4
California	2
North Carolina	2
New York	2
Missouri	1

Clinical Trial Progress for Sorivudine

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	3
Phase 1	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	5
Unknown status	1

Clinical Trial Sponsors for Sorivudine

Sponsor Name

Sponsor Name
Sponsor	Trials
Bristol-Myers Squibb	2
Genentech, Inc.	2
M.D. Anderson Cancer Center	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	6
Other	3
NIH	2